Regenxbio Inc. shares plunged nearly 38% during afternoon trading today after the company released first-quarter 2026 financial results that missed Wall Street expectations on both the bottom and the top line. The company posted a loss of $1.72 per share for Q1, compared with the analyst consensus loss of $1.34 per share. Revenue came in at $6.39 million, materially below the $25.8 million consensus estimate.
The company reported a 93% year-over-year decline in revenue from $89.0 million in the comparable quarter a year earlier. That dramatic fall was driven primarily by the absence of a $70.0 million upfront license payment from Nippon Shinyaku that was recognized in Q1 2025, and by reduced ZOLGENSMA royalty income following the expiration of licensed patents in the U.S. in January 2026.
Regenxbio's cash position weakened considerably over the quarter. Cash, cash equivalents and marketable securities totaled $150.5 million as of March 31, 2026, down from $240.9 million at the end of 2025. Management attributed the decline largely to cash used to fund operating activities, and said the company's cash runway extends only into early 2027. The company did not provide explicit forward-looking revenue guidance alongside the release, a detail that likely intensified investor uncertainty given the magnitude of the revenue shortfall.
Adding to the market's negative read, the company's Chief Medical Officer, Steve Pakola, sold 15,309 shares on May 11, 2026, for a total of $168,705 under a Rule 10b5-1 trading plan. The sales were executed at prices ranging from $11.00 to $11.10 per share.
Market context underscored that the pressure on Regenxbio was company-specific. Major U.S. indices moved higher during the session - with the S&P 500 up +0.84%, the Dow Jones rising +0.77%, and the NASDAQ advancing +1.03% - while Regenxbio shares moved sharply lower. The stock had initially risen in pre-market trading after the company disclosed positive Phase III results for its lead Duchenne muscular dystrophy gene therapy candidate, RGX-202, but losses accelerated once regular trading began.
The pivotal Phase III AFFINITY DUCHENNE trial announced that it met its primary endpoint with high statistical significance. In that trial, 93% of participants reached at least 10% microdystrophin expression at Week 12. Despite the strength of that clinical data - a development that would typically be viewed as a material long-term positive for the company's therapeutic franchise - investors focused on immediate financial metrics.
In effect, a combination of a pronounced revenue miss, a noticeably shorter cash runway, the absence of clear near-term revenue guidance and the insider sale outweighed the positive signal from the AFFINITY DUCHENNE readout in today’s market action. While the successful Phase III outcome is an important element of Regenxbio’s strategic thesis over the long term, the company’s Q1 financials provided a stark reminder of nearer-term funding and execution risks that drove today’s selling pressure.
Context and implications
Investors assessing Regenxbio must weigh two contrasting developments reported today. On one hand, the successful Phase III results for RGX-202 represent a clinically significant milestone. On the other hand, the company's immediate financial trajectory - dominated by a steep revenue decline and a shrinking cash buffer - raises questions about the path to commercial execution and near-term funding needs. Management's decision not to provide explicit revenue guidance compounds that uncertainty.